| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037; and
Division of Clinical Virology, Karolinska Institut, Huddinge, Sweden
The hepatitis B precore Ag (HBeAg) is a secreted nonparticulate version of the viral nucleocapsid hepatitis B core Ag (HBcAg), and its function is unknown. A proportion of HBeAg-specific Th cells evade deletion/anergy in HBeAg-transgenic (Tg) mice and mediate anti-HBe "autoantibody" (autoAb) production after in vivo activation with the appropriate Th cell peptide. This model system was used to determine how secretory HBeAg may effect deletion of Th cells in the periphery. For this purpose, HBeAg-Tg mice were bred with Fas and Fas ligand (FasL)-defective lpr/lpr and gld/gld mutant mice. Fas-FasL interactions mediate activation-induced apoptosis in the periphery. In HBeAg-Tg/+ mice, high-titrated anti-HBe autoAb was produced that was exclusively composed of the IgG1 isotype (i.e., Th2-like profile). In contrast, HBeAg-Tg/lpr and HBeAg-Tg/gld mice produced significantly less anti-HBe autoAb, and the IgG isotype patterns were broadened to include IgG2a, IgG2b and IgG3 as well as IgG1 (i.e., mixed Th1/Th2-like profile). These results suggest that HBeAg-specific Th1 cells are preferentially depleted by Fas-FasL-mediated interactions. The effect of circulating HBeAg on HBcAg-specific Th1 cells was also examined by transferring HBe/HBcAg-specific Th cells into dual HBeAg- and HBcAg-expressing Tg recipient mice. The presence of serum HBeAg ablated the expected Th1-mediated anti-HBc Ab response and shifted it toward a Th2 phenotype. These results suggest that in the context of a hepatitis B viral infection, circulating HBeAg has the potential to preferentially deplete inflammatory HBeAg- and HBcAg-specific Th1 cells that are necessary for viral clearance, thereby promoting hepatitis B virus persistence.
This article has been cited by other articles:
|
|
 |
|
  C. Maenz, C. Loscher, A. Iwanski, and M. Bruns Inhibition of duck hepatitis B virus infection of liver cells by combined treatment with viral e antigen and carbohydrates J. Gen. Virol., December 1, 2008; 89(12): 3016 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Han, W. Yan, W. Guo, D. Xi, Y. Zhou, W. Li, S. Gao, M. Liu, G. Levy, X. Luo, et al. Hepatitis B Virus-induced hFGL2 Transcription Is Dependent on c-Ets-2 and MAPK Signal Pathway J. Biol. Chem., November 21, 2008; 283(47): 32715 - 32729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Duriez, J.-M. Rossignol, and D. Sitterlin The Hepatitis B Virus Precore Protein Is Retrotransported from Endoplasmic Reticulum (ER) to Cytosol through the ER-associated Degradation Pathway J. Biol. Chem., November 21, 2008; 283(47): 32352 - 32360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cooksley, S. Chokshi, Y. Maayan, H. Wedemeyer, P. Andreone, R. Gilson, T. Warnes, S. Paganin, F. Zoulim, D. Frederick, et al. Hepatitis B Virus e Antigen Loss during Adefovir Dipivoxil Therapy Is Associated with Enhanced Virus-Specific CD4+ T-Cell Reactivity Antimicrob. Agents Chemother., January 1, 2008; 52(1): 312 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y-C Chou, M-W Yu, C-F Wu, S-Y Yang, C-L Lin, C-J Liu, W-L Shih, P-J Chen, Y-F Liaw, and C-J Chen Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma Gut, January 1, 2008; 57(1): 91 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Menne, B. C. Tennant, J. L. Gerin, and P. J. Cote Chemoimmunotherapy of Chronic Hepatitis B Virus Infection in the Woodchuck Model Overcomes Immunologic Tolerance and Restores T-Cell Responses to Pre-S and S Regions of the Viral Envelope Protein J. Virol., October 1, 2007; 81(19): 10614 - 10624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Heipertz Jr., T. G. Miller, C. M. Kelley, W. E. Delaney IV, S. A. Locarnini, and H. C. Isom In Vitro Study of the Effects of Precore and Lamivudine-Resistant Mutations on Hepatitis B Virus Replication J. Virol., April 1, 2007; 81(7): 3068 - 3076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Yang, T.-H. Kuo, and L.-P. Ting Human Hepatitis B Viral e Antigen Interacts with Cellular Interleukin-1 Receptor Accessory Protein and Triggers Interleukin-1 Response J. Biol. Chem., November 10, 2006; 281(45): 34525 - 34536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bertoletti and A. J. Gehring The immune response during hepatitis B virus infection J. Gen. Virol., June 1, 2006; 87(6): 1439 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cooper, G. Tal, O. Lider, and Y. Shaul Cytokine Induction by the Hepatitis B Virus Capsid in Macrophages Is Facilitated by Membrane Heparan Sulfate and Involves TLR2 J. Immunol., September 1, 2005; 175(5): 3165 - 3176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, M. Sallberg, J. Hughes, J. Jones, L. G. Guidotti, F. V. Chisari, J.-N. Billaud, and D. R. Milich Immune Tolerance Split between Hepatitis B Virus Precore and Core Proteins J. Virol., March 1, 2005; 79(5): 3016 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Chang, F. Wightman, A. Bartholomeusz, A. Ayres, S. J. Kent, J. Sasadeusz, and S. R. Lewin Reduced Hepatitis B Virus (HBV)-Specific CD4+ T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy J. Virol., March 1, 2005; 79(5): 3038 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Chen, J.-N. Billaud, M. Sallberg, L. G. Guidotti, F. V. Chisari, J. Jones, J. Hughes, and D. R. Milich A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen PNAS, October 12, 2004; 101(41): 14913 - 14918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Menne, C. A. Roneker, B. E. Korba, J. L. Gerin, B. C. Tennant, and P. J. Cote Immunization with Surface Antigen Vaccine Alone and after Treatment with 1-(2-Fluoro-5-Methyl-{beta}-L-Arabinofuranosyl)-Uracil (L-FMAU) Breaks Humoral and Cell-Mediated Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection J. Virol., May 3, 2002; 76(11): 5305 - 5314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Menne, C. A. Roneker, M. Roggendorf, J. L. Gerin, P. J. Cote, and B. C. Tennant Deficiencies in the Acute-Phase Cell-Mediated Immune Response to Viral Antigens Are Associated with Development of Chronic Woodchuck Hepatitis Virus Infection following Neonatal Inoculation J. Virol., February 15, 2002; 76(4): 1769 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Cao, U. Lazdina, I. Desombere, P. Vanlandschoot, D. R. Milich, M. Sallberg, and G. Leroux-Roels Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model J. Virol., July 15, 2001; 75(14): 6359 - 6366. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Kiba, S. Saito, K. Numata, Y. Kon, T. Mizutani, and H. Sekihara Expression of apoptosis on rat liver by hepatic vagus hyperactivity after ventromedial hypothalamic lesioning Am J Physiol Gastrointest Liver Physiol, May 1, 2001; 280(5): G958 - G967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Seeger and W. S. Mason Hepatitis B Virus Biology Microbiol. Mol. Biol. Rev., March 1, 2000; 64(1): 51 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Y. Zhang and J. Summers Enrichment of a Precore-Minus Mutant of Duck Hepatitis B Virus in Experimental Mixed Infections J. Virol., May 1, 1999; 73(5): 3616 - 3622. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
